Mosunetuzumab for systemic lupus erythematosus treatment
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a new drug called mosunetuzumab in people with systemic lupus erythematosus (SLE), a disease where the immune system attacks the body's own tissues. The drug is designed to help control the immune response and reduce lupus symptoms, including kidney involvement if present.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with SLE for at least 6 months before screening
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study
- You must not have an active infection (except nail fungus) or serious infection history
- You cannot have a history of tuberculosis, certain cancers in the past 5 years, or PML (a rare brain infection)
- You must not have received other experimental therapies in the past 30 days or certain other recent treatments (like live vaccines in the past 28 days)
- You cannot have severe or unstable brain/nervous system involvement related to lupus or high bleeding risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called obinutuzumab for people with lupus-related kidney disease, specifically a type called pure membranous nephropathy. The goal is to see if it helps reduce protein leaking into the urine and improves kidney health.
This trial tests whether adding the drug obinutuzumab to standard therapy (mycophenolate and steroids) helps control lupus-related kidney inflammation better than standard therapy alone. It might reduce kidney damage and improve outcomes for people with active lupus nephritis.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This trial tests a new treatment called SNC116 for people with severe lupus who haven't gotten better with standard medicines. It aims to reduce lupus activity by targeting certain immune cells.
This trial tests a new treatment called CM355 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It aims to see if the drug can help control disease activity in patients whose lupus is not well managed by current therapies.
This trial tests a new drug called SIM0278 for people with active lupus nephritis (kidney inflammation caused by lupus). It aims to see if adding this drug to standard treatment is safe and helpful for controlling the disease.
Hear when a new Lupus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.